MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Raises $1.75 Million Through Warrant Exercises to Advance AVERSA Fentanyl Development

Nutriband (NASDAQ: NTRB) announced that 272,671 NTRBW warrants were exercised at a strike price of $6.43, generating approximately $1.75 million in proceeds. The warrants expired Sept. 30 without extension, leaving the company with no remaining tradable warrants. Nutriband plans to use the proceeds primarily to support the remaining clinical development of AVERSA Fentanyl and submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval. AVERSA Fentanyl is being developed as a potential first-of-its-kind opioid patch with abuse-deterrent properties, with estimated peak annual U.S. sales of $80 million to $200 million, according to a 2022 Health Advances market analysis.

To view the full press release, visit https://ibn.fm/ZUBic

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company’s website is www.nutriband.com . Any material contained in or derived from the Company’s websites or any other website is not part of this press release.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

This contant was orignally distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Raises $1.75 Million Through Warrant Exercises to Advance AVERSA Fentanyl Development.